🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prevalence and Risk Factors of Hyperkalemia in Non-Dialysis Chronic Kidney Disease Patients in Community

Recruitingn/aAges 18 Years - anyAllXiujuan Zang
NCT06940414 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to investigate the prevalence and risk factors of hyperkalemia in community-based non-dialysis chronic kidney disease (CKD) patients. The main questions it aims to answer are: 1. What is the prevalence of hyperkalemia in non-dialysis CKD patients in a primary care setting? 2. What are the key risk factors influencing the occurrence of hyperkalemia in this population? Researchers will collect clinical and demographic data from participants across 18 community health centers and use both point-of-care testing (POCT) and laboratory-based methods to measure serum potassium levels and related parameters. Participants will: 1. Provide blood samples for POCT and laboratory testing. 2. Participate in interviews or questionnaires to gather clinical and lifestyle information. The findings will be used to construct a risk prediction model for hyperkalemia

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Aged 18 years or older with stable vital signs, specifically defined as: 1. Body temperature: 36.0°C-38.0°C; 2. Pulse: 50-120 beats/min; 3. Respiratory rate: 10-24 breaths/min; 4. Blood pressure: Systolic blood pressure ≥90 mmHg and diastolic blood pressure ≥60 mmHg. * Willing to participate in the study and sign the informed consent form. * Hematocrit (Hct) level between 25% and 60%. * Confirmed diagnosis of chronic kidney disease (CKD). Exclusion Criteria: * Patients in the unstable phase of acute cardiovascular or cerebrovascular diseases (e.g., acute cerebral infarction, cerebral hemorrhage, or acute coronary syndrome). * Patients in the unstable phase of severe acute diabetic complications (e.g., diabetic ketoacidosis or hyperosmolar hyperglycemic coma). * Patients currently in the acute kidney injury (AKI) stage. * Patients who have started renal replacement therapy. * Pregnant or breastfeeding women. * Patients currently participating in or who have participated in other clinical trials within the past six months. * Patients unable to understand verbal or written instructions, including informed consent content. * Patients unable to cooperate with the study procedures. * Other conditions deemed unsuitable for participation in this clinical trial by the investigator.
💊

What it tests

  • No Intervention
📍

Where

1 site
Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy